Clinical trial
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
NCT00381173 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00381173 |
|---|---|
| Title | A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing |
| Official title | A Phase 1 Open-Label Study of the Safety and Feasibility of ZYC300 Administration With Cyclophosphamide Pre-Dosing |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer, Renal Cancer |
| Intervention type | Drug |
| Interventions | Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing) |
| Enrollment | 22 |
| Start date | Nov 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 27, 2006 |
| Last update posted | May 14, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: